Healthcare Providers and Services
Company Overview of RedPath Integrated Pathology, Inc.
RedPath Integrated Pathology, Inc., a genomics-based cancer diagnostic company, provides molecular analysis to resolve diagnostic dilemmas. The company offers PathFinderTG, a molecular analysis of mutations in genomic DNA for cases where traditional pathology results in an indeterminate, suspicious, or a typical diagnosis. Its PathFinderTG differentiates metastatic, synchronous, and recurrent tumors in various organs, such as breast, lungs, liver, endometrium, and ovaries. The company’s PathFinderTG analysis is validated in pancreas, esophagus, biliary ducts, and brain. It serves pathologists, oncologists, clinicians, and patients. RedPath Integrated Pathology, Inc. was founded in 2004 and i...
2515 Liberty Avenue
Pittsburgh, PA 15222
Founded in 2004
Key Executives for RedPath Integrated Pathology, Inc.
Chief Executive Officer and Director
Founder and Chief Scientific Officer
Vice President of Reimbursement and Payor Relations
Director of Sales & Marketing
Vice President of Sales and Reimbursement
Compensation as of Fiscal Year 2013.
RedPath Integrated Pathology, Inc. Key Developments
RedPath Integrated Pathology, Inc. Launches Accucea Chemistry Test for Pancreatic Cyst Patients
Feb 18 14
RedPath Integrated Pathology, Inc. announced the launch of a new, patent-pending, customized test to accurately measure carcinoembryonic antigen in all pancreatic cyst fluids. Unlike routinely used, commercially available CEA assays, AccuCEA(TM) provides accurate results, even in pancreatic cyst fluid specimens with limited volume and/or high viscosity. Furthermore, AccuCEA provides physicians with more options in the diagnostic work-up of patients by preserving precious fluid and making it available for additional tests. When the amount of pancreatic cyst fluid is limited and CEA testing is prescribed, CEA can be analyzed in diluted fluid. However, dilution of cyst fluid can significantly impact the analytical accuracy of the resulting CEA measurements. RedPath has solved this problem by creating AccuCEA, which provides CEA measurements in diluted cyst fluid that are true to their corresponding neat (undiluted) cyst fluid CEA measurements. Results of the study documenting the accuracy of AccuCEA were presented at the 2013 Digestive Disease Week meeting.
RedPath Integrated Pathology, Inc. Presents at 25th Annual Piper Jaffray Healthcare Conference 2013, Dec-03-2013 04:30 PM
Nov 19 13
RedPath Integrated Pathology, Inc. Presents at 25th Annual Piper Jaffray Healthcare Conference 2013, Dec-03-2013 04:30 PM. Venue: The New York Palace Hotel, 455 Madison Avenue, New York, NY 10022, United States. Speakers: Dennis Morgan Smith, Chief Executive Officer and Director.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|